Status:
COMPLETED
Pioglitazone Incretin Study
Lead Sponsor:
University of Vermont
Collaborating Sponsors:
Takeda
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
Incretin hormones are hormones produced by the gut in response to food intake. These hormones help the body to control the metabolism of glucose (sugar). In particular, two incretin hormones (GLP-1 an...
Eligibility Criteria
Inclusion
- Type 2 diabetes controlled with diet+exercise or metformin monotherapy
- HbA1c less than or equal to 7%
- Women will be non-fertile or practicing birth control
Exclusion
- Acute or chronic medical conditions that would contraindicate participation
- Class III or IV heart failure
- Pregnant or nursing women
- Patients taking antidiabetic medications other than metformin, oral or chronic topical steroids, weight loss agents, antipsychotics, or other drugs that could affect insulin sensitivity or secretion.
- AST or ALT more than 2.5 times the upper limit of normal
- Active alcohol or drug abuse
- Weight greater than 300 pounds
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00656864
Start Date
May 1 2008
End Date
November 1 2010
Last Update
February 2 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Vermont
South Burlington, Vermont, United States, 05403